A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Serum Integrated Screen, Part 1 (NY)
Test Code16973
CPT Codes
Refer to Maternal Serum, Serum Integrated Screen, Part 2 (NY) - (test code 16966) <br /> <br /> **For non-New York patient testing, use test code 16165**
Includes
This will be reported and billed with Maternal Serum, Serum Integrated Screen, Part 2 results.
Preferred Specimen
1.5 mL serum
Minimum Volume
0.8 mL
Instructions
Collect between 9.0 weeks to 13 6/7 weeks.
Must complete patient demographic information using the Maternal Serum Screen Requisition.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 28 days
Refrigerated: 14 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Moderate and gross hemolysis
Methodology
Chemiluminescence (CL) • Immunoassay (IA)
FDA Status
This test was developed and its performance characteristics have been determined by Quest Diagnostics. Performance characteristics refer to the analytical performance of the test.
Setup Schedule
A.M. Sets up 6 days a week.
Report Available
Reports in 3 to 5 days.
Limitations
Refer to Maternal Serum, Serum Integrated Screen, Part 2 (test code 16966)
Clinical Significance
When used in conjunction with part 2 testing, to assess maternal risk for carrying a fetus with down syndrome (trisomy 21), trisomy 18, or a neural tube defect. Both part 1 and part 2 are necessary to generate the risk assessment. These types of tests are standard-of-care in obstetrics.